Skip to main content

Advertisement

SpringerLink
Log in

Role of Recombinant Human Thyrotropin (rhTSH) in the Treatment of Well-Differentiated Thyroid Cancer

  • Review Article
  • Published:
Indian Journal of Surgical Oncology Aims and scope Submit manuscript

Abstract

Since the introduction of radioiodine (RAI) for treatment of well-differentiated thyroid cancer (DTC) more than 50 years ago, prolonged periods of hypothyroidism were routinely used as part of the treatment regimen. Recombinant human TSH (rhTSH) was introduced in the 1990s as a tool to elevate the serum TSH without the need for thyroid hormone withdrawal and symptomatic hypothyroidism. After being initially approved as a diagnostic tool for use in RAI scanning and stimulated thyroglobulin testing, rhTSH was approved as an adjunct to RAI remnant ablation in patients without distant metastases in Europe in 2005 and in the US in 2007. Following successful use of rhTSH for diagnostic purposes, it has been extensively studied for use with therapeutic doses of RAI in the setting of RAI remnant ablation and is now an integral part of DCT therapy. The use of rhTSH in clinical practice in the last decade was coupled with the growing interest in an individualized, risk-stratified approach to the management of patients with DCT. While traditional treatment for DTC included surgery and RAI therapy for all patients, many more recent studies demonstrated the value of selective use of RAI only in patients who will probably benefit from treatment. This manuscript reviews the evolving role of rhTSH in the current risk adapted climate of thyroid cancer management with particular emphasis on the use of rhTSH as an aid to RAI therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, Cooper DS, Schuff KG, Braverman LE, Skarulis MC, Davies TF, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Weintraub BD, Ridgway EC, Ladenson PW (2006) A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab 91:878–884

    Article  PubMed  CAS  Google Scholar 

  2. Lee J, Yun MJ, Nam KH, Chung WY, Soh EY, Park CS (2010) Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid: Off J Am Thyroid Assoc 20:173–179

    Article  Google Scholar 

  3. Mazzaferri EL (2007) Management of low-risk differentiated thyroid cancer. Endocr Pract: Off J Am Coll Endocrinol Am Assoc Clin Endocrinol 13:498–512

    Google Scholar 

  4. Tuttle RM, Rondeau G, Lee NY (2011) A risk-adapted approach to the use of radioactive iodine and external beam radiation in the treatment of well-differentiated thyroid cancer. Cancer Control: J Moffitt Cancer Cent 18:89–95

    Google Scholar 

  5. Hanscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, Reiners C (2006) Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med: Off Publ, Soc Nucl Med 47:648–654

    Google Scholar 

  6. de Keizer B, Hoekstra A, Konijnenberg MW, de Vos F, Lambert B, van Rijk PP, Lips CJ, de Klerk JM (2004) Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer. J Nucl Med: Off Publ, Soc Nucl Med 45:1549–1554

    Google Scholar 

  7. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid: Off J Am Thyroid Assoc 19:1167–1214

    Article  Google Scholar 

  8. Durante C, Filetti S (2011) Management of papillary thyroid cancer patients in absence of postoperative radioiodine remnant ablation: Tailoring Follow-up by neck sonography. The J Clin Endocrinol Metab

  9. Torlontano M, Attard M, Crocetti U, Tumino S, Bruno R, Costante G, D’Azzo G, Meringolo D, Ferretti E, Sacco R, Arturi F, Filetti S (2004) Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab 89:3402–3407

    Article  PubMed  CAS  Google Scholar 

  10. Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, Maurer MS, McIver B, Mullan BP, Oberg AL, Powell CC, van Heerden JA, Goellner JR (2002) Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 26:879–885

    Article  PubMed  Google Scholar 

  11. Sawka AM, Brierley JD, Tsang RW, Thabane L, Rotstein L, Gafni A, Straus S, Goldstein DP (2008) An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin N Am 37:457–480, x

    Article  Google Scholar 

  12. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis M, Maxon HR, Sherman SI (2006) Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid: Off J Am Thyroid Assoc 16:1229–1242

    Article  Google Scholar 

  13. Vaisman F, Shaha A, Fish S, Tuttle R. (2011) Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer. Clin Endocrinol

  14. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A (2010) Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid: Off J Am Thyroid Assoc 20:1341–1349

    Article  CAS  Google Scholar 

  15. Pilli T, Brianzoni E, Capoccetti F, Castagna MG, Fattori S, Poggiu A, Rossi G, Ferretti F, Guarino E, Burroni L, Vattimo A, Cipri C, Pacini F (2007) A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 92:3542–3546

    Article  PubMed  CAS  Google Scholar 

  16. (2011) 81st annual meeting of the American Thyroid Association meeting ABSTRACTS & AGENDA. Thyroid : Off J Am Thyroid Assoc 21:1–111

  17. http://www.itc2010.com/download/ITC2010_programme.pdf

  18. Chianelli M, Todino V, Graziano FM, Panunzi C, Pace D, Guglielmi R, Signore A, Papini E (2009) Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients. Eur J Endocrinol/Eur Federation Endocr Soc 160:431–436

    Article  CAS  Google Scholar 

  19. Taieb D, Sebag F, Cherenko M, Baumstarck-Barrau K, Fortanier C, Farman-Ara B, De Micco C, Vaillant J, Thomas S, Conte-Devolx B, Loundou A, Auquier P, Henry JF, Mundler O (2009) Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study. Clin Endocrinol 71:115–123

    Article  CAS  Google Scholar 

  20. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C (2006) Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 91:926–932

    Article  PubMed  CAS  Google Scholar 

  21. Ma C, Xie J, Liu W, Wang G, Zuo S, Wang X, Wu F (2010) Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer. Cochrane database of systematic reviews (Online):CD008302

  22. Tuttle RM, Brokhin M, Omry G, Martorella AJ, Larson SM, Grewal RK, Fleisher M, Robbins RJ (2008) Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med: Off Publ, Soc Nucl Med 49:764–770

    Google Scholar 

  23. Barbaro D, Boni G, Meucci G, Simi U, Lapi P, Orsini P, Pasquini C, Piazza F, Caciagli M, Mariani G (2003) Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 88:4110–4115

    Article  PubMed  CAS  Google Scholar 

  24. Barbaro D, Boni G, Meucci G, Simi U, Lapi P, Orsini P, Pasquini C, Turco A, Mariani G (2006) Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnants. Nucl Med Commun 27:627–632

    Article  PubMed  CAS  Google Scholar 

  25. Pacini F, Molinaro E, Castagna MG, Lippi F, Ceccarelli C, Agate L, Elisei R, Pinchera A (2002) Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 87:4063–4068

    Article  PubMed  CAS  Google Scholar 

  26. Robbins RJ, Larson SM, Sinha N, Shaha A, Divgi C, Pentlow KS, Ghossein R, Tuttle RM (2002) A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J Nucl Med: Off Publ, Soc Nucl Med 43:1482–1488

    CAS  Google Scholar 

  27. Tuttle RM, Lopez N, Leboeuf R, Minkowitz SM, Grewal R, Brokhin M, Omry G, Larson S (2010) Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. Thyroid: Off J Am Thyroid Assoc 20:257–263

    Article  CAS  Google Scholar 

  28. Maxon HR 3rd, Smith HS (1990) Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin N Am 19:685–718

    Google Scholar 

  29. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M (2006) Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91:2892–2899

    Article  PubMed  CAS  Google Scholar 

  30. Maxon HR 3rd, Englaro EE, Thomas SR, Hertzberg VS, Hinnefeld JD, Chen LS, Smith H, Cummings D, Aden MD (1992) Radioiodine-131 therapy for well-differentiated thyroid cancer–a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med: Off Publ, Soc Nucl Med 33:1132–1136

    Google Scholar 

  31. Wang W, Larson SM, Tuttle RM, Kalaigian H, Kolbert K, Sonenberg M, Robbins RJ (2001) Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid: Off J Am Thyroid Assoc 11:1169–1175

    Article  CAS  Google Scholar 

  32. Rudavsky AZ, Freeman LM (1997) Treatment of scan-negative, thyroglobulin-positive metastatic thyroid cancer using radioiodine 131I and recombinant human thyroid stimulating hormone. J Clin Endocrinol Metab 82:11–14

    Article  PubMed  CAS  Google Scholar 

  33. Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners C, Pacini F (2005) rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr-relat Cancer 12:49–64

    Article  PubMed  CAS  Google Scholar 

  34. Robbins RJ, Driedger A, Magner J (2006) Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid: Off J Am Thyroid Assoc 16:1121–1130

    Article  CAS  Google Scholar 

  35. Driedger AA, Kotowycz N (2004) Two cases of thyroid carcinoma that were not stimulated by recombinant human thyrotropin. J Clin Endocrinol Metab 89:585–590

    Article  PubMed  CAS  Google Scholar 

  36. Taieb D, Jacob T, Zotian E, Mundler O (2004) Lack of efficacy of recombinant human thyrotropin versus thyroid hormone withdrawal for radioiodine therapy imaging in a patient with differentiated thyroid carcinoma lung metastases. Thyroid: Off J Am Thyroid Assoc 14:465–467

    Article  CAS  Google Scholar 

  37. Potzi C, Moameni A, Karanikas G, Preitfellner J, Becherer A, Pirich C, Dudczak R (2006) Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients. Clin Endocrinol 65:519–523

    Article  Google Scholar 

  38. Freudenberg LS, Jentzen W, Petrich T, Fromke C, Marlowe RJ, Heusner T, Brandau W, Knapp WH, Bockisch A (2010) Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons. Eur J Nucl Med Mol Imaging 37:2267–2276

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrinology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Zuckerman Building, Room 834, 1275 York Avenue, New York, NY, 10021, USA

    E. Robenshtok & R. Michael Tuttle

Authors
  1. E. Robenshtok
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Michael Tuttle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Michael Tuttle.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Robenshtok, E., Tuttle, R.M. Role of Recombinant Human Thyrotropin (rhTSH) in the Treatment of Well-Differentiated Thyroid Cancer. Indian J Surg Oncol 3, 182–189 (2012). https://doi.org/10.1007/s13193-011-0115-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13193-011-0115-1

Keywords

Search

Navigation